Onkologie. 2015:9(5):251-254

¨ESMO 2015: Co nového v léčbě mCRC

Jan Bauer

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bauer J. ¨ESMO 2015: Co nového v léčbě mCRC. Onkologie. 2015;9(5):251-254.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hahn S, et al. Clinical performance comparison of RAS mutation detection in plasma and tissue samples from stage IV colorectal cancer patients for first-line anti-EGFR therapy selection. ESMO, 2015, abstract No. 402. Go to original source...
    2. Jones FS, et al. Blood based detection of RAS mutations to guide anti-EGFR therapy in metastatic CRC patients: Concordance of results from circulating tumor DNA and tissue-based RAS testing. ESMO 2015, poster No. 2012. Go to original source...
    3. Scott R, et al. Concordance of RAS mutation status in CRC patients by comparison of results from circulating tumour DNA and tissue-based testing. Ann Oncol. 2015;26: Suppl 4, abstract P-273. Go to original source...
    4. Siravegna G, et al. Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies. J Clin Oncol 33, 2015 (suppl; abstr 11073). Go to original source...
    5. Heinemann V, et al.: A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors (EGFRIs) vs bevacizumab in patients with metastatic colorectal cancer (mCRC). Ann Oncol. 2015;26: Suppl 4, abstract PD-013. Go to original source...
    6. Tamburini E, et al. Cetuximab or Panitumumab versus Bevacizumab in the treatment of first line RAS wild type colorectal cancer: pooled analysis of randomized clinical trials. J Clin Oncol 33:5s, 2015 (suppl; abstr e14634). Go to original source...
    7. Khattak MA, et al.: Role of First-Line Anti-Epidermal Growth Factor Receptor Therapy Compared With Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials. Clinical Colorectal Cancer 2015; Vol. 14 (2): 81-90. Go to original source... Go to PubMed...
    8. Pietrantonio F, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 2015 Jun 5. pii:S1040-8428(15)00114-6. Go to original source...
    9. Aranda E, et al. Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: TheMACRO-2 trial. ESMO 2015, abstract (poster) 2122. Go to original source...
    10. Cremolini C, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 2015; 26(6): 1188-1194. Go to original source...
    11. Heinemann V, et al. Ann Oncol, 2014; 25(2): abstr. O-0030.
    12. Douilard JY, et al. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. European Journal of Cancer 2015; 51: 1231-1242. Go to original source...
    13. Rivera F, et al. Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC. ESMO 2015, abstract No. 2014. Go to original source...
    14. Cheng Al, et al. Association between early tumour shrinkage and outcomes in RAS-wild type patients with metastatic colorectal cancer receiving first-line FOLFOX or FOLFIRI + cetuximab once every 2 weeks in the APEC study. ESMO 2015, abstract No. 2112. Go to original source...
    15. Abad A, et al. Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD). ESMO 2015, abstract No. 2128. Go to original source...
    16. Souglakos J, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)British Journal of Cancer 2006; 94: 798-805. Go to original source... Go to PubMed...
    17. Falcone A, et al. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord OvestJ Clin Oncol 2007; 25: 1670-1676. Go to original source... Go to PubMed...
    18. Masi G, et al. Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. J Natl Cancer Inst 2011; 103: 21-30. Go to original source... Go to PubMed...
    19. Ychou M, et al.: A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol 2013; 20(13): 4289-4297. Go to original source...
    20. Cremolini C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. Ann Oncol. 2015; 26: Suppl 4, abstract LBA-09. Go to original source...
    21. Gruenberger T, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 2015; 26(4): 702-708. Go to original source...
    22. Yanhong Deng, et al. Folfoxiri with or without cetuximab as first-line treatment of patients with non-resectable liver, only metastatic colorectal cancer and KRAS/NRAS wild type (FOCULM study). J Clin Oncol 33, 2015 (suppl 3; abstr TPS798). Go to original source...
    23. Martens U, et al. An open-label 2:1 randomized phase I/II study of Panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first line treatment of patients with non-resectable metastatic colorectal cancer and ras wild type (VOLFI / AIO-KRK-0109). ESMO 2015., abstract No. 2049. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.